Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Meanwhile, the company advanced its competitive positioning with the planned rollout of semaglutide-based GLP-1 therapies in key markets, such as the launch of semaglutide 2.4mg in Mexico starting in April 2025, expanding treatment options for patients with obesity and supporting broader regional market growth
Even as a child I struggled with trying to lose weight
Our Score: 4/5 Our Score: 4/5 Our score is based on the latest data, customer feedback, clinical transparency, and ease of patient onboarding
It is not FDA-approved as a drug product
US$ 20.88
US$ 23.73
US$ 28.51
US$ 23.09
